HC Wainwright Reiterates “Buy” Rating for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ:CMRX)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $11.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 216.09% from the company’s current price.

Separately, Wedbush reiterated an “outperform” rating and set a $6.00 target price on shares of Chimerix in a research report on Tuesday, December 10th.

Chimerix Price Performance

Shares of NASDAQ:CMRX opened at $3.48 on Monday. The stock has a market cap of $312.98 million, a price-to-earnings ratio of -3.70 and a beta of 1.02. The company has a 50 day moving average of $1.61 and a 200-day moving average of $1.14. Chimerix has a one year low of $0.75 and a one year high of $3.66.

Institutional Trading of Chimerix

A number of hedge funds have recently modified their holdings of CMRX. Connor Clark & Lunn Investment Management Ltd. increased its stake in Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares in the last quarter. Valeo Financial Advisors LLC grew its holdings in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 69,505 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of Chimerix in the 2nd quarter valued at $137,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.